Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5 432 M
EBIT 2016 1 403 M
Net income 2016 -45,7 M
Debt 2016 5 265 M
Yield 2016 0,60%
Sales 2017 5 641 M
EBIT 2017 1 484 M
Net income 2017 491 M
Debt 2017 4 321 M
Yield 2017 0,79%
P/E ratio 2016 -
P/E ratio 2017 26,01
EV / Sales2016 3,20x
EV / Sales2017 2,92x
Capitalization 12 138 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
12/01 PERRIGO : Cohen's SAC Capital in $135 million settlement with Elan investors
11/22 PERRIGO COMPANY PLC : ex-dividend day
11/21 PERRIGO COMPANY PLC : Post Earnings Coverage as Perrigo Q3 Results Beat Expectat..
11/10 PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
11/10 PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
11/10 PERRIGO : reports 3Q loss
11/10 PERRIGO : to review options for multiple sclerosis drug royalties
11/09 PERRIGO : PRGO) Pops 3.61% for November 09
11/08 PERRIGO : PRGO) is Trading Lower on Unusual Volume for November 08
11/07PERRIGO COMPANY PLC : quaterly earnings release
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 19
Average target price 105 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John T. Hendrickson President, Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Judy L. Brown Executive VP, Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Gerald K. Kunkle Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY12 138
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
More Results